Skip to main content

AEMPS authorizes the clinical trial to study HIPRA's COVID-19 vaccine in adolescents between 12 and 17 years old


The Spanish Agency of Medicines and Health Products (AEMPS) has authorized a clinical trial of the vaccine against COVID-19 from the biotechnology pharmaceutical company HIPRA to find out whether the booster dose of the vaccine is safe in adolescents between 12 and under 18 years old who have previously been vaccinated with 2 doses of Comirnaty (Pfizer) and to confirm whether this booster dose increases the immune response (defenses) against COVID-19.

The study, in which 300 adolescents will participate, will involve 5 hospitals in Spain: Hospital Vall d'Hebron in Barcelona, Hospital Josep Trueta in Girona, HM Universitario Puerta del Sur in Madrid, HM Montepríncipe in Madrid and Hospital Universitario La Paz in Madrid.

Each hospital will soon provide a space on its website so that those interested can register. As they are minors, they must inform their father, mother or legal guardian in order to proceed with the enrollment.

The study will be evaluated by the Ethics Committee of HM Hospitales and by the Spanish Agency of Medicines and Health Products (AEMPS).

COVID19 Trial Adolescents